Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Small Cell
  • Enzyme Inhibitors
  • Hydroxamic Acids
  • Lung Neoplasms
  • Metalloendopeptidases

abstract

  • Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.

publication date

  • November 15, 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2002.02.108

PubMed ID

  • 12431965

Additional Document Info

start page

  • 4434

end page

  • 9

volume

  • 20

number

  • 22